Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PA-317 by PersonGen BioTherapeutics (Suzhou) for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
PA-317 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According...
PA-317 by PersonGen BioTherapeutics (Suzhou) for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
PA-317 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase I for Anaplastic Large Cell Lymphoma (ALCL)....
PA-317 by PersonGen BioTherapeutics (Suzhou) for Acute Lymphoblastic Lymphoma: Likelihood of Approval
PA-317 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase I for Acute Lymphoblastic Lymphoma. According to...
PA-317 by PersonGen BioTherapeutics (Suzhou) for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval
PA-317 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase I for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy....